Bioeq’s Lucentis Biosimilar Is Given EU Go-Ahead
Launch Dates And Financial Terms Of A Marketing Deal With Teva Remain Under Wraps
Executive Summary
Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.